D9S168 microsatellite alteration predicts a poor prognosis in patients with clear cell renal cell carcinoma and correlates with the down-regulation of protein tyrosine phosphatase receptor delta

Cancer

Volumn 117, Issue 18, 2011, Pages 4201-4211

  Li, Xiaopan ^a   Tan, Xiaojie ^a   Yu, Yongwei ^b   Chen, Haitang ^a   Chang, Wenjun ^a   Hou, Jianguo ^b   Xu, Danfeng ^c   Ma, Liye ^b   Cao, Guangwen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

clear cell; gene expression; loss of heterozygosity; microsatellite instability; prognosis; prospective study; renal cell carcinoma

Indexed keywords

PROTEIN TYROSINE PHOSPHATASE RECEPTOR DELTA; RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 14Q; CHROMOSOME 3P; CHROMOSOME 9P; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DEATH; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; KIDNEY TUBULE CELL; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROSATELLITE INSTABILITY; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNTRANSLATED REGION;

CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DOWN-REGULATION; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; MIDDLE AGED; PROGNOSIS; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 2;

EID: 80052472619     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26028     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96. (Pubitemid 351521864)
2. Shablak A, Hawkins RE, Rothwell DG, et al. T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective. Clin Cancer Res. 2009; 15: 6503-6510.
3. Gupta K, Miller JD, Li JZ, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008; 34: 193-205.
4. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002; 20: 4559-4566. (Pubitemid 35402959)
5. Aben KK, Luth TK, Janssen-Heijnen ML, et al. No improvement in renal cell carcinoma survival: a population-based study in the Netherlands. Eur J Cancer. 2008; 44: 1701-1709.
6. Jensen HK, Donskov F, Marcussen N, et al. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol. 2009; 27: 4709-4717.
7. Gutwein P, Schramme A, Sinke N, et al. Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. Eur J Cancer. 2009; 45: 478-489.
8. Crispen PL, Boorjian SA, Lohse CM, et al. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer. 2008; 113: 450-460.
9. Thompson RH, Dong H, Kwon ED,. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res. 2007; 13: 709s-715s.
10. Bigot P, Lughezzani G, Karakiewicz P, et al. The prognostic value of erythrocyte polyamine in the post-nephrectomy stratification of renal cell carcinoma specific mortality. J Urol. 2010; 183: 486-491.
11. Vasudev NS, Sim S, Cairns DA, et al. Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma. Br J Cancer. 2009; 101: 1175-1182.
12. Garcia JA, Cowey CL, Godley PA,. Renal cell carcinoma. Curr Opin Oncol. 2009; 21: 266-271.
13. Kempkensteffen C, Hinz S, Christoph F, et al. Expression parameters of the inhibitors of apoptosis cIAP1 and cIAP2 in renal cell carcinomas and their prognostic relevance. Int J Cancer. 2007; 120: 1081-1086. (Pubitemid 46214309)
14. Young AC, Craven RA, Cohen D, et al. Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res. 2009; 15: 7582-7592.
15. Sukosd F, Kuroda N, Beothe T, et al. Deletion of chromosome 3p14.2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma. Cancer Res. 2003; 63: 455-457. (Pubitemid 36152507)
16. Chen M, Ye Y, Yang H, et al. Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer. 2009; 125: 2342-2348.
17. Grady B, Goharderakhshan R, Chang J, et al. Frequently deleted loci on chromosome 9 may harbor several tumor suppressor genes in human renal cell carcinoma. J Urol. 2001; 166: 1088-1092. (Pubitemid 32751050)
18. Alimov A, Sundelin B, Wang N, et al. Loss of 14q31-q32.2 in renal cell carcinoma is associated with high malignancy grade and poor survival. Int J Oncol. 2004; 25: 179-185.
19. Kaku H, Ito S, Ebara S, et al. Positive correlation between allelic loss at chromosome 14q24-31 and poor prognosis of patients with renal cell carcinoma. Urology. 2004; 64: 176-181. (Pubitemid 38887609)
20. Hirata H, Matsuyama H, Matsumoto H, et al. Deletion mapping of 18q in conventional renal cell carcinoma. Cancer Genet Cytogenet. 2005; 163: 101-105. (Pubitemid 41758450)
21. Perego RA, Corizzato M, Brambilla P, et al. Concentration and microsatellite status of plasma DNA for monitoring patients with renal carcinoma. Eur J Cancer. 2008; 44: 1039-1047.
22. Pecina-SLaus N, Gall-TroSelj K, SLaus M, et al. Genetic changes of the E-cadherin and APC tumour suppressor genes in clear cell renal cell carcinoma. Pathology. 2004; 36: 145-151. (Pubitemid 38507875)
23. Man YG, Burgar A,. An antigen unmasking protocol that satisfies both immunohistochemistry and subsequent PCR amplification. Pathol Res Pract. 2003; 199: 815-825. (Pubitemid 38239875)
24. Schurr P, Wolter S, Kaifi J, et al. Microsatellite DNA alterations of gastrointestinal stromal tumors are predictive for outcome. Clin Cancer Res. 2006; 12: 5151-5157. (Pubitemid 44453343)
25. Veeriah S, Brennan C, Meng S, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A. 2009; 106: 9435-9440.
26. Wu L, Chang W, Zhao J, et al. Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer. Clin Cancer Res. 2010; 16: 3760-3768.
27. Solomon DA, Kim JS, Cronin JC, et al. Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res. 2008; 68: 10300-10306.
28. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008; 455: 1069-1075.
29. Purdie KJ, Harwood CA, Gulati A, et al. Single nucleotide polymorphism array analysis defines a specific genetic fingerprint for well-differentiated cutaneous SCCs. J Invest Dermatol. 2009; 129: 1562-1568.
30. Cheung KJ, Delaney A, Ben-Neriah S, et al. High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy-neutral loss of heterozygosity and copy number alterations that target single genes. Genes Chromosomes Cancer. 2010; 49: 669-681.
31. Tada M, Kanai F, Tanaka Y, et al. Prognostic significance of genetic alterations detected by high-density single nucleotide polymorphism array in gastric cancer. Cancer Sci. 2010; 101: 1261-1269.
32. Kohno T, Otsuka A, Girard L, et al. A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. Genes Chromosomes Cancer. 2010; 49: 342-352.
33. Purdie KJ, Lambert SR, Teh MT, et al. Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis. Genes Chromosomes Cancer. 2007; 46: 661-669. (Pubitemid 46802333)
34. Nair P, De Preter K, Vandesompele J, et al. Aberrant splicing of the PTPRD gene mimics microdeletions identified at this locus in neuroblastomas. Genes Chromosomes Cancer. 2008; 47: 197-202. (Pubitemid 351162850)
35. Chan TA, Glockner S, Yi JM, et al. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis [serial online]. PLoS Med. 2008; 5: e114.